Form 4: Bausch Health Director Steven Miller Reports Share Acquisition and Disposal

Director Steven Miller reports acquisition of restricted share units and disposal of common shares.

Summary

• Steven D Miller, a director of Bausch Health Companies Inc., reported transactions involving the company's securities.
• On May 16, 2025, Miller acquired 54,347 common shares through the award of restricted share units (RSUs) with a value of $250,000.
• These RSUs vest immediately prior to the next Annual Meeting of Shareholders and are settled in common shares.
• On the same day, Miller disposed of 10,000 common shares held indirectly through an IRA.
• Following these transactions, Miller directly owns 229,224 common shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing primarily reflects routine compensation and portfolio adjustments. The RSU grant is a positive sign of alignment, while the share disposal is a minor negative.

Positives

• The acquisition of RSUs demonstrates continued alignment of the director's interests with those of the shareholders.

Negatives

• The disposal of 10,000 shares, while potentially for personal financial management, could be perceived negatively by some investors.

Future Outlook

The RSUs vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the actions of company insiders, such as directors and officers, regarding the company's stock.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash and equity, with RSUs being a common component.
• The vesting schedule of RSUs is typically tied to continued service or performance milestones.
• The size of the RSU grant ($250,000) is within a reasonable range for non-employee directors at companies of similar size and complexity to Bausch Health.
• Comparing Bausch Health's director compensation practices with those of peers like Teva Pharmaceutical Industries or Mylan (now Viatris) would provide further context.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign of alignment between management and shareholder interests.
• The disposal of shares could create some uncertainty, but the amount is relatively small.

Next Steps

• Monitor future Form 4 filings by Steven Miller and other insiders for further insights into their investment activities.
• Track the performance of Bausch Health's stock price following this disclosure.

Key Dates

Keywords

Bausch Health, Director, Steven Miller, RSUs, Share Acquisition, Share Disposal, Form 4, Beneficial Ownership